• PDS Biotech to Participate at the B. Riley Securities 3rd Annual Oncology Conference

    来源: Nasdaq GlobeNewswire / 13 1月 2023 07:00:00   America/Chicago

    FLORHAM PARK, N.J., Jan. 13, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that its management will participate in a fireside chat at the B. Riley Securities 3rd Annual Oncology Conference being held virtually on January 18-19, 2023.

    B. Riley Securities 3rd Annual Oncology Conference
    Fireside Chat: Thursday, January 19, 2023
    Time: 1:00 PM EST
    Virtual viewers: Livestream

    About PDS Biotechnology
    PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer and infectious disease immunotherapies based on our proprietary Versamune® and Infectimune™ T cell-activating technology platforms. We believe our targeted Versamune® based candidates have the potential to overcome the limitations of current immunotherapy by inducing large quantities of high-quality, potent polyfunctional tumor specific CD4+ helper and CD8+ killer T cells. To date, our lead Versamune® clinical candidate, PDS0101, has demonstrated the potential to reduce tumors and stabilize disease in combination with approved and investigational therapeutics in patients with a broad range of HPV-expressing cancers in multiple Phase 2 clinical trials. Our Infectimune™ based vaccines have also demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also powerful T cell responses, including long-lasting memory T cell responses in pre-clinical studies to date. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

    Versamune® is a registered trademark and Infectimune™ is a trademark of PDS Biotechnology.

    Investor Contacts:
    Deanne Randolph
    PDS Biotech
    Phone: +1 (908) 517-3613
    drandolph@pdsbiotech.com

    Rich Cockrell
    CG Capital
    Phone: +1 (404) 736-3838
    pdsb@cg.capital  

    Media Contacts: 
    Tiberend Strategic Advisors, Inc.
    Dave Schemelia 
    Phone: +1 (609) 468-9325 
    dschemelia@tiberend.com  

    Bill Borden 
    Phone: +1 (732) 910-1620 
    bborden@tiberend.com


    Primary Logo

分享